Results 131 to 140 of about 38,260 (253)

On 3‐MMC: A Cathinone I Have Come to Know and Love

Anthropology of Consciousness, EarlyView.
ABSTRACT This article attempts to complicate the mythology of a compound in a state of becoming. I will trace lightly its origins as a cultural disruptor and how I am implicated in this imperative. Introducing you to 3‐MMC will require multiple modes of storytelling and taking of liberties, drawing on literature reviews, practice‐based research, prose,
Carmen Ostrander
wiley   +1 more source

Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models. [PDF]

Curr Top Behav Neurosci
Bedillion MF, Moore CF, Weerts EM, Arout CA, Harris HM, Haney M.   +5 more
europepmc   +1 more source

A qualitative investigation of the lived experiences of adults with anxiety and related disorders and ADHD: Interconnectedness of symptoms and implications for improving care

British Journal of Clinical Psychology, EarlyView.
Abstract Background Attention‐deficit/hyperactivity disorder (ADHD) is highly prevalent in adults with anxiety and related disorders (ARDs). Quantitative research on this clinical population is mixed, with some studies suggesting that anxiety is protective against some symptoms of ADHD and others in which co‐occurring ARDs and ADHD are linked to poorer
Arij Alarachi, Heather McNeely, Karen Rowa, Randi E. McCabe   +3 more
wiley   +1 more source

Trends in cannabis use and cannabis use disorder among parents in the U.S., 2012-2024. [PDF]

Addict Behav
Dontha M, Chitty TC, Waddell JT, Kemp EC, Patel H, Pelham WE.   +5 more
europepmc   +1 more source

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

Nationwide outcomes of cardiac surgery in patients with cannabis use disorder. [PDF]

J Cardiothorac Surg
Dewan KC, Mahboubi R, Xu S, Maigrot JA, An C, Zhou G, Ferre JLD, Koroukian SM, Weiss AJ, Soltesz EG.   +9 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Psychiatrists' opinions about non-medicalization of cannabis use disorder in Iran. [PDF]

Discov Ment Health
Namazi H, Sayyah M.
europepmc   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Trends in cannabis use disorder and treatment by race and ethnicity, 2002-2019. [PDF]

Front Psychiatry
Triguero Roura M, Vora A, Eschliman EL, Mauro PM.   +3 more
europepmc   +1 more source